BIO earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E 50.08. Updated 2026-07-23.
Bio-Rad Laboratories (BIO) Research Hub
Bio-Rad Laboratories (BIO) trades on NYSE, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 369.32 USD (-2.03%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 50.08, market cap 8.29B. This hub links to the full technical, earnings and options research available for BIO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NYSE, US |
| Last close | 369.32 USD (-2.03%) |
| 52-week range | 270 USD – 394.29 USD |
| Trend regime | Range |
| 14-day RSI | 59.9 (Bullish) |
| Trailing P/E | 50.08 |
| Market cap | 8.29B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for BIO
Covered Call on BIO: how it works, illustrative setup around the real 369.32 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BIO: how it works, illustrative setup around the real 369.32 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BIO: how it works, illustrative setup around the real 369.32 USD price, max profit/loss, breakeven and when to use it. Educational.
BIO technical analysis: range, last 369.32 USD, RSI 59.9, 52w range 270 USD–394.29 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BIO in?
Bio-Rad Laboratories (BIO) is classified under Healthcare (Medical - Devices), listed on NYSE, US.
Is BIO in an uptrend or downtrend?
As of 2026-09-11, BIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BIO's trailing P/E ratio?
BIO's trailing P/E is 50.08, with a market cap of 8.29B. See the earnings research page for full valuation detail.
When does BIO next report earnings?
BIO is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of 1.75 USD.